Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has received positive opinion from the CHMP, the scientific committee of the European Medicines Agency or EMEA, for its human granulocyte colony stimulating factor G-CSF product.
Subscribe to our email newsletter
The European Commission is now expected to grant marketing authorization for this product, which will be marketed in the EU by Teva under the brand name TevaGrastim. G-CSF is mainly indicated for the treatment of chemotherapy-induced neutropenia.
Amir Elstein, executive vice president, global resources of Teva, said: “We are very pleased to receive the first positive opinion for a biosimilar G-CSF product in the EU and believe that it shows the strength of our biotechnology R&D capabilities.”